Biomotion Sciences Ordinary SharesNASDAQ: SLXN

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Biomotion Sciences Ordinary Shares is in the Healthcare sector

Biomotion Sciences Ordinary Shares is in the Biotechnology industry

Biomotion Sciences Ordinary Shares is headquartered in Israel

Biomotion Sciences Ordinary Shares initial public offering (IPO) was on 07 April 2021

https://silexion.com

No, Biomotion Sciences Ordinary Shares is not included in the S&P 500 index

No, Biomotion Sciences Ordinary Shares is not included in the NASDAQ 100 index

No, Biomotion Sciences Ordinary Shares is not included in the Dow Jones index

No data